AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
With a market cap of 384.45B, AbbVie(ABBV) trades at $217.39. The stock has a price-to-earnings ratio of 107.38 and currently yields dividends of 3.1%.
On 2026-05-30, AbbVie(ABBV) stock moved within a range of $214.90 to $219.60. With shares now at $217.39, the stock is trading +1.2% above its intraday low and -1.0% below the session's peak.
Trading activity shows a volume of 7.62M, compared to an average daily volume of 5.42M.
The stock's 52-week range extends from a low of $181.73 to a high of $244.81.
The stock's 52-week range extends from a low of $181.73 to a high of $244.81.
ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and...
AbbVie (ABBV) announced that the European Commission has authorized an expanded label for Venclyxto to include use in combination with acalabrutinib and use in...
AbbVie (ABBV) just received U.S. FDA approval for Decnupaz, the first antibody drug conjugate cleared to treat blastic plasmacytoid dendritic cell neoplasm, an...
Analyst ratings
73%
of 33 ratingsMore ABBV News
If you are wondering whether AbbVie stock still offers value after a strong run, it is important to see how different valuation methods line up against the curr...
According to recent news, AbbVie announced on Friday a positive CHMP opinion for MAVIRET® for the treatment of acute hepatitis C infection. Deckers, on May 21,...
Key Points The weight loss opportunity is a significant one for companies and investors -- and companies involved have seen their shares soar. Analysts predic...
AbbVie recently received positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use supporting approval of MAVIRET fo...
Key Points Pfizer's dividend yield is far higher than AbbVie's, but the key issue is whether the payout is safe. AbbVie has been a dividend growth beast for s...
AbbVie (NYSE:ABBV) received positive European Medicines Agency opinions for Boey®, its new aesthetics product. The EMA also issued a favorable opinion for MAVI...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.